- RecruitingPHASE2, PHASE3
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
This study is testing a new medicine, ozanimod, for children aged 2-17 with moderate to severe ulcerative colitis that hasn't responded well to other treatments. We want to see if it helps them feel better and stay well.
For: Colitis, UlcerativeUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
This study is looking into a new medication called Ozanimod for people with moderately to severely active Crohn's disease. Researchers want to see if it can help keep symptoms under control and reduce inflammation in the gut over time.
For: Moderately to Severely Active Crohn's DiseaseFrance · Bulgaria · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This study is looking at a medicine called ozanimod for people with Crohn's disease that is moderate to severe. It wants to see how well the medicine helps reduce their symptoms and improve their gut health over a long period. Researchers will also check how it affects COVID-19 antibody levels.
For: Moderately to Severely Active Crohn's DiseaseGermany · Hungary · Slovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
This study is testing a new medicine, Ozanimod, for people in the UK with moderate to severe ulcerative colitis. It's looking at how well the medicine helps control symptoms and improve the gut, as well as checking for any side effects. It's a key stage of testing before being widely available.
For: Ulcerative colitisBelgium · Romania · Poland